The LGG + Oxp regimen reduces tumor burden by 52% compared to Oxp alone while simultaneously preserving intestinal barrier integrity, as evidenced by the upregulation of Occludin and Mucin2. This dual benefit overcomes the dose-limiting toxicity of chemotherapy, enabling prolonged treatment adherence. The gene discussed is OCLN; the disease is neoplasm.